Literature DB >> 9698028

Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation.

J Astermark1, O Björgell, E Lindén, S Lethagen, P Nilsson, E Berntorp.   

Abstract

OBJECTIVES: To evaluate the recurrence rate after deep calf-vein thrombosis treated with 6 weeks of oral anticoagulation. DESIGN AND
SUBJECTS: A 2 year follow-up of 126 consecutive patients admitted to the Department of Internal Medicine with venographically verified deep calf-vein thrombosis.
RESULTS: One hundred and twenty-six patients were treated with warfarin for 6 weeks, 18 of them having had a previous episode of venous thrombosis (DVT). Eleven patients (8.7%) suffered a recurrent thromboembolic episode within 2 years, four of which were within the first 3 months. Eight of those without a history of DVT had a recurrence (7.4%). Three of these were activated protein C (APC)-resistant, one was protein C-deficient and one had malignant melanoma. Eight patients (6.3%) reported minor haemorrhagic complications, but no major bleeding was seen.
CONCLUSION: Our data support the use of a 6 week regimen of secondary oral prophylaxis after a first episode of deep calf-vein thrombosis in patients without a permanent risk factor. Whether individuals with inherited thrombophilia require prolonged treatment remains to be evaluated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9698028     DOI: 10.1046/j.1365-2796.1998.00318.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  4 in total

Review 1.  Landmark trials in thrombotic vascular disease: a critical appraisal of potential practice-changing trials in 2016-2017.

Authors:  Andrea Cervi; James Demetrios Douketis
Journal:  Intern Emerg Med       Date:  2018-07-27       Impact factor: 3.397

Review 2.  Treatment of Isolated Below the Knee Deep Vein Thrombosis.

Authors:  Gualtiero Palareti; Michelangelo Sartori
Journal:  Curr Atheroscler Rep       Date:  2016-07       Impact factor: 5.113

3.  Platelet-Monocyte Aggregates and C-Reactive Protein are Associated with VTE in Older Surgical Patients.

Authors:  Lauren Shih; David Kaplan; Larry W Kraiss; T Charles Casper; Robert C Pendleton; Christopher L Peters; Mark A Supiano; Guy A Zimmerman; Andrew S Weyrich; Matthew T Rondina
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

4.  Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).

Authors:  Jayne Tullett; Ellen Murray; Linda Nichols; Roger Holder; Will Lester; Peter Rose; F D Richard Hobbs; David Fitzmaurice
Journal:  BMC Cardiovasc Disord       Date:  2013-03-09       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.